Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.
You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
2/16/2021
In 2019, Grünenthal entered into a partnership with Mesoblast, a world leader in cellular medicines, to develop the investigational medicine MPC-06-ID, an innovative cell therapy for patients who suffer from chronic low back pain associated with degenerative disc disease, and who have exhausted conservative treatment options.
2/8/2021
On Tuesday of last week, Grünenthal initiated a recall of all batches of Palexia® 20 mg/ml oral solution and Palexia® 4 mg/ml oral solution and halted production until further notice due to a bacterial contamination issue. Palexia® tablets are not affected by the contamination and are not being recalled.
2/1/2021
As a science-driven company, it is our commitment to provide safe and effective oral contraceptives so that women are in a position to make their own decision and choices about their reproductive health.
10/28/2020
Grünenthal considers the outbreak and spread of Covid-19 to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.
10/19/2020
Grünenthal has issued notice to AcelRx Pharmaceuticals, Inc. to terminate the supply license agreement for Zalviso™.
6/30/2020
Grünenthal issued notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic® (lesinurad)1 and Duzallo® (lesinurad and allopurinol, currently not marketed)2 for the treatment of chronic hyperuricaemia in adults with gout, who have not achieved target serum uric acid levels with an adequate dose of a Xanthine Oxidase Inhibitor (XOI) alone, from the market in Europe. Zurampic and Duzallo will not be marketed in Latin America.
6/24/2020
The German federal parliament adopted an amendment to the Contergan Foundation Act on 19 June 2020, whereby benefits to thalidomide victims, once granted, cannot be revoked. This includes the thalidomide pension, which is paid by the Contergan Foundation. Only in special cases, such as deliberate deception, is it possible to withdraw benefits.
Florian Dieckmann
Head Global Communication
Grünenthal GmbH
52099 Aachen
Phone +49 241 569-2555